High density lipoprotein cholesterol and the risk of all-cause mortality among U.S. veterans

Clinical Journal of the American Society of Nephrology

Volumn 11, Issue 10, 2016, Pages 1784-1793

  Bowe, Benjamin ^a   Xie, Yan ^a   Xian, Hong ^a,d   Balasubramanian, Sumitra ^a   Zayed, Mohamed A ^a,b,e   Al Aly, Ziyad ^a,c,f  

^a Research and Medical Service   (United States)

^b Campus Box 8109 Surgery   (United States)

^c VA St Louis Health Care System   (United States)

^d SAINT LOUIS UNIVERSITY   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular diseases; Cholesterol, HDL; Chronic kidney disease; Coronary artery disease; Epidemiology and outcomes; Humans; Hypercholesterolemia; Lipids; Mortality; Mortality risk; United States veterans

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANGIOPLASTY; ARTICLE; CLINICAL OUTCOME; COMORBIDITY; CORONARY ARTERY DISEASE; CURRENT PROCEDURAL TERMINOLOGY; DEATH; ESTIMATED GLOMERULAR FILTRATION RATE; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MORTALITY; SENSITIVITY ANALYSIS; AGED; BLOOD; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; KIDNEY DISEASE; LONGITUDINAL STUDY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; UNITED STATES; VETERAN;

AGED; CHOLESTEROL, HDL; COMORBIDITY; CORONARY ARTERY DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY DISEASES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE; UNITED STATES; VETERANS;

EID: 85011431682     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00730116     Document Type: Article

References (31)

1. Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B, Bian A, Shintani A, Fogo AB, Linton MF, Fazio S, Kon V: Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 60: 2372–2379, 2012
2. Trevisan R, Dodesini AR, Lepore G: Lipids and renal disease. J Am Soc Nephrol 17[Suppl 2]: S145–S147, 2006
3. Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Kränkel N, Kania G, Zewinger S, Akhmedov A, Shi Y, Martin T, Perisa D, Winnik S, Müller MF, Sester U, Wernicke G, Jung A, Gutteck U, Eriksson U, Geisel J, Deanfield J, von Eckardstein A, Lüscher TF, Fliser D, Bahlmann FH, Landmesser U: Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 38: 754–768, 2013
4. Jacek R, Anna G, Danilo F, Timo S, Andrzej W: Chronic kidney disease - different role for HDL? Curr Med Chem 21: 2910–2916, 2014
5. Zewinger S, Speer T, Kleber ME, Scharnagl H, Woitas R, Lepper PM, Pfahler K, Seiler S, Heine GH, März W, Silbernagel G, Fliser D: HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol 25: 1073– 1082, 2014
6. Lamprea-Montealegre JA, Astor BC, McClelland RL, de Boer IH, Burke GL, Sibley CT, O’Leary D, Sharrett AR, Szklo M: CKD, plasma lipids, and common carotid intima-media thickness: Results from the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol 7: 1777–1785, 2012
7. Vaziri ND, Navab M, Fogelman AM: HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 6: 287–296, 2010
8. Vaziri ND: Causes of dysregulation of lipid metabolism in chronic renal failure. Semin Dial 22: 644–651, 2009
9. Wang F, Zheng J, Ye P, Luo L, Bai Y, Xu R, Sheng L, Xiao T, Wu H: Association of high-density lipoprotein cholesterol with the estimated glomerular filtration rate in a community-based population. PLoS One 8: e79738, 2013
10. Baragetti A, Norata GD, Sarcina C, Rastelli F, Grigore L, Garlaschelli K, Uboldi P, Baragetti I, Pozzi C, Catapano AL: High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. J Intern Med 274: 252–262, 2013
11. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ: Plasma lipids and risk of developing renal dysfunction: The atherosclerosis risk in communities study. Kidney Int 58: 293–301, 2000
12. Murphy PA, Cowper DC, Seppala G, Stroupe KT, Hynes DM: Veterans Health Administration inpatient and outpatient care data: An overview. Eff Clin Pract 5[Suppl]: E4, 2002
13. Oddone EZ, Eisen S: Veterans Affairs Research and Development: Using science to improve health care for veterans. N C Med J 69: 35–37, 2008
14. US Department of Veterans Affairs: VIReC Research User Guide: VHA Medical SAS Outpatient Datasets FY2006, Hines, IL, US Department of Veterans Affairs VA Information Resource Center, 2007
15. US Department of Veterans Affairs: VIReC Research User Guide: VHA Medical SAS Inpatient Datasets FY2006, Hines, IL, US Department of Veterans Affairs VA Information Resource Center, 2007
16. US Department of Veterans Affairs: VIReC Research User Guide: Veterans Health Administration Decision Support System Clinical National Data Extracts, Hines, IL, US Department of Veterans Affairs VA Information Resource Center, 2009
17. Du Bois D, Du Bois EF: A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5: 303–311, 1989
18. Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z: Rate of kidney function decline and risk of hospitalizations in stage 3A CKD. Clin J Am Soc Nephrol 10: 1946–1955, 2015
19. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43: 1130–1139, 2005
20. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z: Proton pump inhibitors and risk of incident CKD and progression to ESRD [published online ahead of print April 14, 2016]. J AmSoc Nephrol
21. Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z: Estimated GFR trajectories of people entering CKD stage 4 and subsequent kidney disease outcomes and mortality [published online ahead of print March 4, 2016]. Am J Kidney Dis doi:10.1053/j.ajkd.2016.02.039
22. Xie Y, Bowe B, Xian H, Balasubramanian S, Al-Aly Z: Renal function trajectories in patients with prior improved eGFR slopes and risk of death. PLoS One 11: e0149283, 2016
23. Bowe B, Xie Y, Xian H, Balasubramanian S, Al-Aly Z: Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney Int 89: 886– 896, 2016
24. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O’Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S: Plasma HDL cholesterol and risk of myocardial infarction: A Mendelian randomisation study. Lancet 380: 572–580, 2012
25. Huang CY, Lin FY, Shih CM, Au HK, Chang YJ, Nakagami H, Morishita R, Chang NC, Shyu KG, Chen JW: Moderate to high concentrations of high-density lipoprotein from healthy subjects paradoxically impair human endothelial progenitor cells and related angiogenesis by activating Rho-associated kinase pathways. Arterioscler Thromb Vasc Biol 32: 2405–2417, 2012
26. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. NEngl J Med 357: 1301–1310, 2007
27. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators: Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367: 2089–2099, 2012
28. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109–2122, 2007
29. Kalil RS, Wang JH, de Boer IH, Mathew RO, Ix JH, Asif A, Shi X, Boden WE: Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: A post hoc analysis of the AIM-HIGH trial. Kidney Int 87: 1250–1257, 2015
30. de Boer IH, Brunzell JD: HDL in CKD: How good is the “good cholesterol?”. J Am Soc Nephrol 25: 871–874, 2014
31. Müller-Deile J, Schmitt R: HDL in CKD: Not protective any longer? Kidney Int 85: 712, 2014